Another 12 months of failures

It’s been 14 months since the May 2024 strategic review and what’s to show for it? Diddly squat.

Below are some key Starpharma comments from the June Quarterly Report from 2024 that followed the review. The progress and achievements against these goals has been woeful IMO. Where are the resignations? Where are the sackings? Where’s the company apology to shareholders? Looking forward to the company’s QR commentary later this week.

From June 2024 QR:
’the entire team at Starpharma has been highly focused on achieving specific milestones relating to the three strategic imperatives’ : Cute

’Our immediate focus includes securing a licensing deal for a priority DEP asset, driving forward the DEP HER2 radiopharmaceutical assets, advancing our partnerships’
: No deals. Radiopharmaceutical stalled. Silence.

‘We have realigned our internal resources to rigorously pursue these strategic imperatives’ : Cute

’the comp has been acutely focused on achieving its goal of securing a DEP licensing deal and has recruited an additional business development resource to support these efforts’ : Hasn’t resulted in a deal

’Starpharma announced plans to advance its DEP® HER2 radiodiagnostic candidate towards a first-in-human clinical study in 2025.’ : Not happening

’Starpharma’s partnered research programs, including those with MSD and Genentech, continued during the quarter.’ : 1 year on still no licence

P.S. Very interestingly MSD and Genentech were not mentioned at all in the most recent Quarterly Report. That could be a clue to a future reveal later this year. I’ll be keenly wanting to see renewed comments giving confidence that both these partnerships are indeed still active.